Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JACDS Discusses Problems Expected from Ban on Dispensing Point Services
November 21, 2011
- Plaintiffs Appeal to the Supreme Court: Iressa Appeal Trial
November 18, 2011
- 6 Indian Generics Companies Including Zydus Form Association, to Start Operations This Month
November 18, 2011
- JPMA Postpones Announcement of Views on TPP,“Will Not Comment Based on Speculation”
November 17, 2011
- Plaintiffs Say High Court Ruling over Iressa “Completely Denies Goals in Medical Administration”
November 17, 2011
- Top JPWA Officials Stress Importance of Wholesalers in Urgent Press Conference
November 17, 2011
- NEDO Decides to Provide Assistance to Four Projects to Develop Bio-Pharmaceutical Manufacturing Technology
November 16, 2011
- JPMA Campaign Highlights Value of New Drug Development
November 15, 2011
- Foreign Countries Interested in Japan’s New Promotion of Generics: IGPA Annual Conference
November 14, 2011
- Premium for Development of New Drugs Is Fiscal Neutrality System: Mr Kamoya of JPMA
November 11, 2011
- JPWA's Bessho Says Promotion of Unit-Priced Contracts by Product First and Foremost
November 11, 2011
- Trial of Premium for New Drug Development Should Continue: Dr Suzuki of JMA
November 1, 2011
- Prescription Doubts Found in 3.15% of Prescriptions, 70% of Those Were Changed: JPA Survey
October 28, 2011
- FPMAJ to Request DPJ to Make Premiums Permanent
October 27, 2011
- JPA’s Yamamoto Calls for Deliberation on TPP after Clarification
October 25, 2011
- JMA Openly Opposes TPP; JPA, JDA, JNA Express Concern
October 24, 2011
- FPMAJ Drafting GLs on Radiation Testing for Crude Drugs
October 21, 2011
- JPMA Makes Pamphlets to Promote Understanding of PC
October 20, 2011
- JPMA to Draw Up Opinion on TPP During This Month
October 20, 2011
- Toray to Join JPMA in November
October 20, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…